Monthly Archives: May 2012

Zyvex Technologies and ENVE Composites Introduce the World's First Nano-Enhanced Carbon Fiber …

Posted on by

Exclusive partnership now offers highly specialized, durable, World-Cup-winning downhill rim

COLUMBUS, Ohio - The world's first molecular nanotechnology company, Zyvex Technologies, and ENVE Composites announced an exclusive partnership to provide a bicycle rim specifically for downhill mountain biking that uses the latest advanced materials comprised of nano-enhanced carbon fiber. This new bicycle rim gives a significant competitive advantage to the downhill cycling market as proven during the last year in development and testing. The ENVE DH rim provides performance benefits to all downhill cyclists including those that compete at the highest levels of World Cup racing.

ENVE used Zyvex Technologies' nano-enhanced carbon fiber technology called Arovex, which is a carbon nanotube and graphene engineered composite material that uses the proprietary Kentera technology to create chemical bonds on the carbon nanotubes. It provides an advantage in toughness without compromising strength. It also protects from fracture damage. ENVE has an exclusive license for this advanced technology for cycling applications.

ENVE developed the first nano-enhanced carbon fiber downhill bike with the intention of its riders winning a World Cup. After being in development for over a year, the rim carried ENVE sponsored rider Greg Minnaar (see photo) to victory at the 2012 World Cup opener in South Africa.

"The ENVE-Zyvex partnership introduces the first carbon fiber rim specifically designed for the downhill cyclist. During development and testing the wheels have won over 50 podiums in competitions around the world. These results validate ENVE's success using Zyvex's Arovex. Downhill racing is extreme in nature. The fact that these new rims have survived the most challenging tracks in the world make them truly one-of-a-kind," noted Jason Schiers, founder of ENVE Composites.

Most notable is an unprecedented increase in durability, strength, and stiffness over traditional alloy offerings on the market. Often, top level teams will need to change rims more than 180 times during a season. World Cup downhill racing champion Steve Peat raced on one pair of the ENVE DH wheels during the entire 2011 season. Traditional aluminum rims historically lasted him a mere one to three runs.

"Nano-enhanced carbon fiber wheels are changing what people expect from a bike's ride quality. Being the first nano-enhanced carbon fiber downhill clincher to win a World Cup is difficult. We are changing the game. The new DH rims are the best riding and the most durable rims on the market today," concluded Schiers.

The new rim design shows significant technical and competitive advantages in this demanding market.

Some scientists believe the ability to move and combine individual atoms and molecules will revolutionize the production of every human-made object leading to a potential new technology revolution.

"The use of carbon atoms in the 21st century will be as significant as the use of silicon in the 20th century.Zyvex Technologies is the first company to globally commercialize nano-enhanced products from carbon atoms," said Lance Criscuolo, president of Zyvex Technologies. "The value of building a $40-billion supply chain in less than four years means that partners like Composites One convey these advances to companies like ENVE that are constantly innovating products. Our advanced materials weigh less and have increased strength. We are changing the way products are manufactured and perform," said Criscuolo.

See the original post:

Zyvex Technologies and ENVE Composites Introduce the World's First Nano-Enhanced Carbon Fiber ...

Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine'

Posted on by

Newswise New Brunswick, N.J., May 15, 2012 With recent advancements in technology and biomedical informatics, a more personalized approach to prescribing cancer treatment and developing these therapies is preferred over one-size-fits-all methods. The Cancer Institute of New Jersey (CINJ) has been on the cutting-edge of this movement and is now launching a more concrete effort that is poised to change the way that molecular and genetic information is being used to diagnose and treat cancer an initiative known as precision medicine also known to many as personalized medicine. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.

Research has shown that cancer is not one disease, but rather a collection of diseases. Each cancer sub-type boasts its own individual molecular makeup, which in many cases results in cancer growth and resistance to cancer-killing drugs. By further defining the molecular profile of various cancer subtypes, investigators hope to apply this information toward developing targeted therapies. Large scale efforts on the national and local levels including those at CINJ have been underway to collect correlating clinical and genomic data to use as a road map in determining diagnosis, prognosis and course of treatment. With CINJs newly-established precision medicine initiative, specialized investigators will further integrate that information using state-of-the-art technology to better catalogue and expedite the flow of data from researcher to doctor to patient and in turn back to the researcher.

Leading CINJs initiative for precision medicine is Lorna Rodriguez, MD, PhD, who served as CINJs chief of gynecologic oncology from 2000 until this year before being asked to take on this new role. Dr. Rodriguez has years of experience running her own investigator-initiated clinical trials including research on cancer metastasis, drug resistance and the CD44 cell surface receptor and the role it plays in ovarian cancer metastasis. She feels the impact of precision medicine both on patients and on the health/biomedical communities will be tremendous. For the most part, clinicians are forced to rely on limited information to make treatment decisions, as there hasnt been a mechanism to collect and catalogue such comprehensive data as tissue samples, patient history and treatment records to create the tumor profiles necessary for more personalized treatments, noted Rodriguez, who is also a professor of obstetrics, gynecology and reproductive sciences at UMDNJ-Robert Wood Johnson Medical School. By compiling and further curating a collection of molecular and genetic data that will help drive new targeted therapies, we will be helping patients better manage their disease.

This also will translate into cost savings, as no longer will doctors need to rely on hit-or-miss medicine, continued Rodriguez, who also performs gynecologic cancer surgeries and helps patients navigate chemotherapy options. Currently, if one treatment is found to be ineffective, others are used -- and they come at a cost, both financially and in terms of lost time when the patient might have received effective treatment. With the prospects of precision medicine, we are moving closer to an era where we will be able to tailor cancer treatments to perfectly fit individualized patient profiles. This will also lead us to a better understanding in diagnosing disease and providing a prognosis.

The breast cancer drug trastuzumab is one example of how genomic information is helping to drive targeted cancer therapies. Study has shown that trastuzumab is effective for 20 percent of breast cancer patients whose cancer cells make too much of the HER2-positive protein. Because a genetic test can indicate whether a patient has the HER2-positive profile, doctors can better determine whether trastuzumab might be an effective treatment for them.

About The Cancer Institute of New Jersey The Cancer Institute of New Jersey (www.cinj.org) is the states first and only National Cancer Institute-designated Comprehensive Cancer Center dedicated to improving the detection, treatment and care of patients with cancer, and serving as an education resource for cancer prevention. CINJs physician-scientists engage in translational research, transforming their laboratory discoveries into clinical practice, quite literally bringing research to life. To make a tax-deductible gift to support CINJ, call 732-235-8614 or visit http://www.cinjfoundation.org. CINJ is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. Follow us on Facebook at http://www.facebook.com/TheCINJ.

The CINJ Network is comprised of hospitals throughout the state and provides the highest quality cancer care and rapid dissemination of important discoveries into the community. Flagship Hospital: Robert Wood Johnson University Hospital. System Partner: Meridian Health (Jersey Shore University Medical Center, Ocean Medical Center, Riverview Medical Center, Southern Ocean Medical Center, and Bayshore Community Hospital). Major Clinical Research Affiliate Hospitals: Carol G. Simon Cancer Center at Morristown Medical Center, Carol G. Simon Cancer Center at Overlook Medical Center, and Cooper University Hospital. Affiliate Hospitals: CentraState Healthcare System, JFK Medical Center, Robert Wood Johnson University Hospital Hamilton (CINJ Hamilton), Somerset Medical Center, The University Hospital/UMDNJ-New Jersey Medical School*, and University Medical Center at Princeton. *Academic Affiliate

###

View original post here:

Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine'

CNIO scientists successfully test the first gene therapy against aging-associated decline

Posted on by

Public release date: 14-May-2012 [ | E-mail | Share ]

Contact: Juan J. Gomez juanj.gomez@cnio.es 34-917-328-000-4060 Centro Nacional de Investigaciones Oncologicas (CNIO)

A number of studies have shown that it is possible to lengthen the average life of individuals of many species, including mammals, by acting on specific genes. To date, however, this has meant altering the animals' genes permanently from the embryonic stage an approach impracticable in humans. Researchers at the Spanish National Cancer Research Centre (CNIO), led by its director Mara Blasco, have proved that mouse lifespan can be extended by the application in adult life of a single treatment acting directly on the animal's genes. And they have done so using gene therapy, a strategy never before employed to combat ageing. The therapy has been found to be safe and effective in mice.

The results are published today in the journal EMBO Molecular Medicine. The CNIO team, in collaboration with Eduard Ayuso and Ftima Bosch of the Centre of Animal Biotechnology and Gene Therapy at the Universitat Autnoma de Barcelona (UAB), treated adult (one-year-old) and aged (two-year-old) mice, with the gene therapy delivering a "rejuvenating" effect in both cases, according to the authors.

Mice treated at the age of one lived longer by 24% on average, and those treated at the age of two, by 13%. The therapy, furthermore, produced an appreciable improvement in the animals' health, delaying the onset of age-related diseases like osteoporosis and insulin resistance and achieving improved readings on ageing indicators like neuromuscular coordination.

The gene therapy utilised consisted of treating the animals with a DNA-modified virus, the viral genes having been replaced by those of the telomerase enzyme, with a key role in ageing. Telomerase repairs the extremes of chromosomes, known as telomeres, and in doing so slows the cell's and therefore the body's biological clock. When the animal is infected, the virus acts as a vehicle depositing the telomerase gene in the cells.

This study "shows that it is possible to develop a telomerase-based anti-ageing gene therapy without increasing the incidence of cancer", the authors affirm. "Aged organisms accumulate damage in their DNA due to telomere shortening, [this study] finds that a gene therapy based on telomerase production can repair or delay this kind of damage", they add.

'Resetting' the biological clock

Telomeres are the caps that protect the end of chromosomes, but they cannot do so indefinitely: each time the cell divides the telomeres get shorter, until they are so short that they lose all functionality. The cell, as a result, stops dividing and ages or dies. Telomerase gets round this by preventing telomeres from shortening or even rebuilding them. What it does, in essence, is stop or reset the cell's biological clock.

But in most cells the telomerase gene is only active before birth; the cells of an adult organism, with few exceptions, have no telomerase. The exceptions in question are adult stem cells and cancer cells, which divide limitlessly and are therefore immortal in fact several studies have shown that telomerase expression is the key to the immortality of tumour cells.

See the original post:

CNIO scientists successfully test the first gene therapy against aging-associated decline

Touhou Remix E.37 (Other) Undefined Fantastic Medley 2 – Video

Posted on by

14-05-2012 07:10 Title: Suite Seirensen Circle: NEETS Album: three stars Original composer: ZUN From: Undefined Fantastic Object Of course, I can't upload songs in a playslit without including some medleys. The first medley of the Extra Playlist, by NEETS. I like how they included most of the musics from the game, and how each song, while unique, stay in the spirit of the whole medley. My personnal favorites are Sky Ruin, Beware The Sealed Cloud Route, The Traditional Old Man and the Stylish Girl, The Tiger-Patterned Bishamonten and Cosmic Mind... Include: At the End of Spring Interdimensional Voyage of a Ghostly Passenger Ship Captain Murasa Sky Ruin The Sealed Cloud Route Beware the Umbrella Left There Forever UFO Romance in the Night Sky Fires of Hokkai The Traditional Old Man and the Stylish Girl Heian Alien A Tiny, Tiny, Clever Commander Rural Makai City Esoteria The Tiger-Patterned Bishamonten Emotional Skyscraper ~ Cosmic Mind ___________________________________________________________ If you want to upload the video, copy/paste the URL on this link: I don't own the music nor the picture used in this video.

Visit link:

Touhou Remix E.37 (Other) Undefined Fantastic Medley 2 - Video

Child’s Mind (Tribute to HDSounDL) – Video

Posted on by

14-05-2012 23:03 Composed by: Taniuichi Hideki From: Gyakkyou Burai Kaiji Ultimate Survivor Original Soundtrack Pictures from Deviant Art and Pokememes I really like this song. It's feel and power are just astounding. It is fairly repetitive, yet I never get tired of it! I also really like the title. It just gives the song that much more meaning and serves as a reminder of what I have left behind while growing up. The main reason I uploaded this was to remember and pay tribute to HDSounDL. He/She had an awesome account with hours of amazing music. I just found out that he/she had her account suspended and wanted to upload something to thank him/her for all of the music even if it isn't up any more.

Follow this link:

Child's Mind (Tribute to HDSounDL) - Video

you got me losing my mind | J

Posted on by

15-05-2012 10:43 I OWN NOTHING. It's been a long time 🙂 But here I am with a new video! It has only clips from the fourth season...just to show you how much this season has been full of beautiful little moments between my forever and ever otp ^_^ It's nothing special really, but I wanted to keep it simple 🙂 I'll upload the scenes of the mentalist as soon as possible...most likely when the season is already over 😉 I'm so excited for the season finale!! Let me know what you think of the video, enjoy guys 😀

Go here to see the original:

you got me losing my mind | J

How to Share Your Business Photos Online – Discreetly

Posted on by

You have just returned from a corporate retreat or some other business event that was well-documented with several amateur photographers. Now you want to share all of these pictures amongst your co-workers. The challenge is that you want to keep them private to the participants and not plaster them all over the Internets. What to do?

Assume that your requirements are to satisfy the ultra-paranoid in the group and also find something that is dirt simple to use. You don't want to make everyone join a new social network just to see the photos; most of us have too many logins already. That leaves out most of the microblogging sites. And you don't want to have to worry that someone will click on the wrong button andinadvertentlyshare the entire photo collection with the universe, including the press, competitors and so on.

Facebook, Instagram, Google+ and many other social-networking sites aren't very good at setting up discrete group-privacy controls, so they are out of the running for our purposes. And while there are dozens of file-sharing sites such as Box.net and Evernote, the idea is to find something that is designed around uploading and sharing images.

With that in mind, we looked at the following five services:

None of these services is perfect, but they fall into two broad categories: those that have better privacy controls and those that are easier to use.

Let's look at our requirements in more detail:

First, we want a service that can create a private space that doesn't appear on search engines and can't be discovered by unauthorized users. Photobucket and Shutterfly both do this, by setting up a special URL (Photobucket.com/groupname or Groupname.shutterfly.com) for your group. In Photobucket, for example, you have three choices for each album's privacy controls: everyone can see them, no one else can see them, or you can password protect them by invitation only. The latter is perfect for this application, and you can set up an album password so that only those folks who know the password can see and download the photos. (See screenshot below.) Shutterfly has similar options with its Share Sites feature.

The problem with both Photobucket and Shutterfly is that you need to become a member to upload photos: That is fine if you havejusta few shutterbugs in your group, but if everyone wants to be able to contribute images, it can become cumbersome.

Link:

How to Share Your Business Photos Online - Discreetly

Cabo Viejo Luxury Vacation Rentals Now Available on Bobzio.com; The Cost to Market a Property Is Zero

Posted on by

Luxury Cabo Viejo Vacation Rentals available on bobzio.com. This fabulous rental was newly listed. The cost to list was nothing since the owner is one of the first 20,000 to create an account.Houston, TX (PRWEB) May 15, 2012 Cabo Viejo is simply the best new vacation destination in Cabo San Lucas. Located inside the world famous community of Pedregal, Cabo Viejo is an ultra luxurious 5 star ...

Read more:

Cabo Viejo Luxury Vacation Rentals Now Available on Bobzio.com; The Cost to Market a Property Is Zero

How to generate leads on LinkedIn

Posted on by

Anita Windisman Special to Globe and Mail Update Published Monday, May. 14, 2012 6:00AM EDT Last updated Tuesday, May. 15, 2012 7:18AM EDT

With over 135 million members in over 200 countries and over 4 million users in Canada, LinkedIn is the largest site for business professionals. Consider it an online Rolodex that is constantly updated. Following are 10 ways to use LinkedIn for lead generation for your small business.

Optimizing your personal profile.

The first five tips focus on optimizing your own profile making it both captivating and informative in order to be found by your target audience known as inbound lead generation.

1. Write a descriptive headline. Your headline is the sentence that appears just below your name. Rather than just stating your title and company, make it a short descriptive phrase that provides a snapshot of the product or service and the benefit you provide. You only have 120 characters to work with, so make every word count. For example: Certified Management Consultant, Award-winning writer, helps people with expertise to be recognized as thought-leaders.

2. Upload a professional photo. You know the saying; a picture is worth a thousand words. Make sure you upload a professional photo of yourself, preferably in colour and against a light or neutral background. Its best if you wear professional attire. Crop your photo to show your head and shoulders and leave your kids and pets out of the shot! A friendly photo of yourself will draw people into you. LinkedIn statistics prove that a profile with a photo is seven times more likely to be viewed than one that without a photo.

3. Tell your story under the summary section. Are you passionate about your business and the work you do? Do you have a certain philosophy about how you serve customers? Why did you decided to start your business? This is where you can show how you are unique. Also ensure that you summarize your experience here incorporating key words that relate to your business. For this section, write in full sentences in the first person. With 2,000 characters as your limit, three to four short paragraphs will suffice.

4. Add specialties and skills. There are two places in your profile where you can list your expertise. One is in the specialties section below your summary and the other is under skills where you can add up to 50 of them. Make sure you pay extra attention to skills, because this one of the ways in which you will be found when someone conducts a search using key words on LinkedIn. Get specific, using descriptive terms such as: project engineering, wedding photography, resume writing, lifestyle coaching.

5. Get recommendations. In order to have a 100 per cent complete profile on LinkedIn you will have to add at least three recommendations to your profile. This is the place where you can ask your satisfied customers to provide a short testimonial for you. After all, nothing beats a word of mouth referral.

After your profile is complete, you need to get active on LinkedIn to not only increase your visibility to your target audience but you will also come across new prospects.

Link:

How to generate leads on LinkedIn

From Saucy Pics To Passwords: How To Share Sensitive Information

Posted on by

Raise your hand if youve shared a username and password with someone over IM? Ever share a document with your SSN or other extremely sensitive information without protecting it? How about if youve sent, erm scandalous pics to your significant other? Thanks to the internet, we share more than ever, and so quickly and easily, that we do it without a second thought. Thats great, but it may be time you learn a little about how to do that sharing in a more secure fashion.

Title image remixed from Mayer George Vladimirovich and mkabakov.

Here well walk through the easiest and most secure ways to share files, passwords and other data with people you trust. There are countless other methods out there, but these are our favourites. The method you use to share data should depend on what youre sending, how secure you want that material to be, and how willing you are to take proper security methods.

If youre just sending a username, password or other line of text (like a credit card number), protect your info with a few simple tricks:

Sometimes all it takes to increase your security is a little obscurity, and thats what this method is all about. You send the sensitive data over separate channels so that only the recipient is likely to have context for what it all means. Lets say you wanted to share a username and password with someone over the internet. Heres the basic idea:

1. In an email, send the username with an accompanying message something like Ive texted you the FTP password. 2. Text the password separately, with no context. 3. The recipient receives the password, saves it elsewhere and deletes the text message.

Even if your recipient doesnt delete the message (which you cant count on), a snoop would have no context for what it applies to. The basic idea could work in any direction, as long as youre separating the context from the information. Is it 100 per cent foolproof? Absolutely not. But its better than nothing, which is what many of us are doing now.

If you want to get even more creative, you could send someone the first half of the password via SMS, the second half via email, and let the recipient know over IM how its been broken up. That way, a thief would have to have access to both the email, IM account and the phone. You get the idea.

Password management service LastPass is still one of the most secure ways to create and store passwords. If your recipient is also using it (or if you can convince them of how great it is and get them signed up), sharing passwords and other small notes securely is extremely easy. Just pop into your LastPass vault, click the Share link next to the password or secure note you want to share, type in your recipients email address, and LastPass will take care of the rest securely. If youre sharing login credentials, you can choose to share the actual password (so your recipient can learn what it is) or just share access to the credentials in question, so your friend or colleague can log without actually learning your password. For more info on how to share passwords with LastPass, check out our how-to on the subject.

If you need to send full documents like paperwork for your job or a saucy photo youll need the help of an external service. Here are our favourite ways to securely send files.

Go here to see the original:

From Saucy Pics To Passwords: How To Share Sensitive Information

At Content Creators, journalists practice their craft and get paid

Posted on by

May 15, 2012

By Julia Scott Tim Collie stumbled upon a universal truth while building his news startup, Content Creators. Most people dont like their website. The design is bad, or they dont know how to upload videos. The content stagnates, and the site becomes a calling card appended with excuses.

Imagine then, that you get a cold call from Collie, 51.

Were story tellers, his pitch goes. Weve looked at your website. We believe we can help provide you with content and videos.

Talk about full service. Content Creators offers ghostwriting, editing, website design, photography, video, social media, and any other kind of content creation you can think of. Folks who design websites dont typically follow up by providing content and keeping the thing bug-free.

Content Creators does. In fact, it is rare that they are hired to create a website and not contribute the content.

Its one reason why the start up, barely three years old, makes enough to pay out of state college tuition for Collies two sons.

We are willing to work with people who have basic skills, he said. Not that he and his two partners, photographer and videographer Andrew Innerarity and business manager Jodie Knofsky, have left their day jobs. Collie edits the political news website Newsmax.com.

Content Creators is based in South Florida and covers three counties, Broward, Palm Beach, and Miami-Dade. Instead of having a main office, Collie and his partners work from home and on the road. Were kind of virtual, he said. We can move anywhere.

Eighty percent of the work is done by Collie and his two partners. The rest is contractors. Expenses are minimal. Gas money eats up a chunk of change. Indemnity insurance is another big ticket at a few hundred bucks a month.

Originally posted here:

At Content Creators, journalists practice their craft and get paid

New Mobile Application Rates Smiles – Find Out How People Are Loving Their Smiles More Than Ever

Posted on by

A new mobile application allows a professional cosmetic dentist in San Francisco grade users smile and give feedback on ways a licensed cosmetic dentist can improve lives. This amazing new mobile application will allow anyone to anonymously upload peoples smile for grading.San Francisco, Ca (PRWEB) May 15, 2012 Dr Jorge Peter Rabanus is a leading cosmetic dentist in San Francisco and has just ...

Continue reading here:

New Mobile Application Rates Smiles - Find Out How People Are Loving Their Smiles More Than Ever

US Army internal medicine Masters, Fellows honored by American College of Physicians

Posted on by

Public release date: 15-May-2012 [ | E-mail | Share ]

Contact: Zina Poletz zpoletz@webershandwick.com 612-719-2024 Weber Shandwick Worldwide

FORT KNOX, Ky., May 15, 2012 The U.S. Army Medical Department announced today the election of two of its own to Mastership in the American College of Physicians (MACP). Only 43 medical leaders from around the world who have achieved eminence through their contributions to the field of internal medicine in at least one area, such as practice, teaching, research or volunteerism, were awarded a Mastership in 2012. One of the Masters, Col. Gregory J. Argyros, M.D., MACP, who is board-certified in critical care medicine, pulmonology and internal medicine, is director of education, training and research for the Joint Task Force National Capital Region Medical, and professor of medicine at the Uniformed Services University of the Health Sciences. He previously served as chief of medicine and director of the internal medicine residency program at Walter Reed Army Medical Center, and as the ACP Army Chapter Governor from 2005-2009. In addition, Dr. Argyros has received numerous teaching awards over the years.

Recently retired as an Army colonel after a 27-year career, Alan J. Magill, M.D., MACP, was also honored as a Master by the College. Dr. Magill is currently a program manager at the Defense Advanced Research Projects Agency, where he develops effective interventions in the event of an influenza epidemic. He previously served as director of the Division of Experimental Therapeutics at the Walter Reed Army Institute of Research, and is an attending physician with the Infectious Disease Service at Walter Reed National Military Medical Center. He also teaches at the Uniformed Services University of the Health Sciences. Dr. Magill has held leadership positions in infectious disease at the National Institute of Health, International Society of Travel Medicine, American Society of Tropical Medicine and Hygiene, and other organizations.

"That two Army physicians were inducted as Masters by the American College of Physicians speaks to the high quality of physicians who choose to make the Army their career and the extraordinary opportunities Army medicine offers them," said Col. Jeanne Tofferi, M.D., MPH, FACP, internal medicine consultant to the Army Surgeon General. "Both of them have made tremendous contributions to our nation through teaching, medical practice and research."

On April 19, during the ACP annual meeting in New Orleans, six Army internal medicine physicians and subspecialists joined their Army ACP Chapter Governor, Col. Lisa Zacher, M.D., FACP, for a convocation ceremony during which they were inducted as Fellows of the American College of Physicians (FACP). These physicians included: Lt. Col. Michael G. Rossman, M.D. (Rheumatology), Daniel W. Franks, D.O. (Internal Medicine), Maj. Kimberly C. Salazar (Allergy/Immunology), Maj. Paige E. Waterman, M.D. (Infectious Disease), Anne B. Rossignol, M.D. (Hospice Care & Palliative Medicine) and Mark Garfinkle, M.D. (Internal Medicine).

Criteria for Fellowship include board certification by the American Board of Internal Medicine, recognition by other internists for excellence and skill in medical practice, teaching or research, and commitment to continued education and advanced training. Fellows of ACP are recommended by their peers based on character, ethics and excellence in medical practice, and undergo the review by ACP's Credentials Subcommittee.

"The Army makes board certification and continuing medical education a top priority," said Col. Zacher, who is also the pulmonary consultant to the Army surgeon general and chief, Department of Medicine, Brooke Army Medical Center. "The fact that so many Army physicians have become Fellows of the ACP speaks to their professional excellence in internal medicine and dedication to the highest quality of patient care."

The following Army internists and subspecialists were elected as Fellows in 2012 (listed by Army medical center or affiliation):

Walter Reed National Military Medical Center (Washington, D.C.) Col. Ronald D. DeGuzman, M.D. (Allergy/Immunology); Maj. Fouad J. Moawad, M.D. (Gastroenterology); Maj. James E. Moon, M.D. (Internal Medicine); Maj. Kristopher M. Paolino, M.D. (Infectious Disease); Maj. Sheri K. Dennison, M.D. (Hematology/Oncology); Maj. Aaron B. Holley, M.D. (Pulmonology/Critical Care Medicine); Maj. Jeffrey S. Kunz, M.D. (Cardiology); Maj. Kevin M. Woods, M.D. (Cardiology); Maj. Ganesh Veerappan, M.D. (Gastroenterology); Lt. Col. Paige E. Waterman, M.D. (Infectious Disease ); Maj. Jason A. Regules, M.D. (Infectious Disease)

The rest is here:

US Army internal medicine Masters, Fellows honored by American College of Physicians

The medicine cabinet quiz

Posted on by

Most medicine cabinets contain a jumble of over-the-counter health products, but knowing what to use, when, can be confusing. Just because a medication is sold without a prescription doesn't mean it is harmless, and some old standbys can do more harm than good. Based on consultations with experts and reference materials, here is a deceptively easy quiz from The Wall Street Journal to test your home-remedy literacy.

1. You have a headache. Should you take: A) Advil (ibuprofen) B) Tylenol (acetaminophen) C) Aspirin

Answer: A, B or C

All of them will relieve a simple headache, but through different means and with different side effects.

Advil and Motrin (ibuprofen), Aleve (naproxen sodium) and aspirin all reduce pain by fighting inflammation, which also makes them particularly useful for combating arthritis, tooth pain, menstrual cramps and muscle sprains. But they can cause stomach bleeding, so people with peptic ulcers, liver, kidney or heart disease should talk to their doctors before taking them.

Aspirin has the added benefit of preventing blood clots, which is why taking one daily can lower the risk of cardiovascular disease. But aspirin shouldn't be used by people who have low blood pressure or open wounds, or by children who have the flu or chickenpox due to the risk of Reye's syndrome, a rare neurological disorder.

Tylenol (acetaminophen) works by calming pain signals in the brain. But it can cause liver damage if you regularly have three or more alcoholic drinks a day or take a higher dosage than recommended.

All in all, ibuprofen is arguably the strongest, but aspirin works faster, naproxen lasts longer and acetaminophen is safer if you have stomach problems (and aren't a heavy drinker). A few brands contain both acetaminophen and aspirin, but don't mix them on your own and don't take any of them for more than five days straight, since they can cause "rebound" headaches, in which the body feels withdrawal when they wear off.

2. To clean a cut or scrape, it is best to use: A) Hydrogen peroxide B) Isopropyl (rubbing) alcohol C) Neither D) Both

Answer: C

Excerpt from:

The medicine cabinet quiz

BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

Posted on by

WALTHAM, Mass., May 14, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Mayo Medical Laboratory (Mayo) now offers galectin-3 testing services to its laboratory customers and physicians. Mayo will offer the BGM Galectin-3TM test, which was cleared by the U.S. Food and Drug Administration in November 2010, as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Galectin-3 testing provides physicians with clinical information on fibrosis formation and cardiac remodeling, which are important biological processes in the development and progression of heart failure. BG Medicine plans to continue to expand commercial availability of its BGM Galectin-3 test through major U.S. laboratories.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD - News) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine has also developed CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release address our beliefs regarding the clinical utility of galectin-3 testing and our plans to expand commercial availability of galectin-3 testing services. Forward-looking statements are based on management's current expectations and involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Read more:

BG Medicine, Inc. Announces Availability of Galectin-3 Diagnostic Testing Through Mayo Medical Laboratories

Welcome Molecules to Medicine the newest blog at #SciAmBlogs

Posted on by

I am very excited to announce the latest addition to the #SciAmBlogs network Molecules to Medicine, by Dr. Judy Stone.

Judy Stone, MD is an infectious disease specialist, experienced in conducting clinical research. She is the author of Conducting Clinical Research, the essential guide to the topic. As she says, she survived 25 years in solo practice in rural Cumberland, Maryland, and is now broadening her horizons. She particularly loves writing about ethical issues, and tilting at windmills in her advocacy for social justice. As part of her overall desire to save the world when she grows up, she has become especially interested in neglected tropical diseases. When not slaving over hot patients, she can be found playing with photography, friends dogs, or in her garden.

You can check out many years worth of archives on her old blog Politics, Science, and Other Assorted Musings, or follow her on Twitter @drjudystone.

If you are a regular reader of the Scientific American Guest Blog, you have probably read several of Dr.Stones previous posts:

Molecules to Medicine: Clinical Trials for Beginners Molecules to Medicine: From Test-Tube to Medicine Chest Lillys Shocker, or the Post-Marketing Blues Molecules to Medicine: Pharma Trumps HIPAA? Molecules to Medicine: Should pepper spray be put on (clinical) trial? Molecules to Medicine: FDA at a Crossroadsa Tough Place to Be Molecules to Medicine: Plan B: The Tradition of Politics at the FDA Molecules to Medicine: Conscience Clauses versus Refusal: An Historical Perspective Molecules to Medicine: When Religion Collides with Medical Care: Who Decides What Is Right for You? A Taste of #TEDMED 2012: Appetizers A Taste of #TEDMED 2012: Main Course Molecules to Medicine: Have You Thanked a Clinical Researcher Today? Molecules to Medicine: Public Health or Impaired Penises?

Now go and say Hi to Judy in the comments on her first post, then subscribe to or bookmark her blog so you dont miss the future posts.

Continue reading here:

Welcome Molecules to Medicine the newest blog at #SciAmBlogs

BG Medicine Announces Publication of First Study on Use of Galectin-3 in Selection of Drug Therapy in Heart Failure

Posted on by

WALTHAM, Mass., May 14, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that results from a sub-study of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) trial were published online in the current issue of the European Heart Journal.1 Study results demonstrated that patients with blood levels of galectin-3 below 19.0 ng/mL at the start of the trial derived significant clinical benefit from rosuvastatin (statin) treatment. By contrast, no clinical benefit from rosuvastatin treatment was observed among participants with higher levels of galectin-3.

The galectin-3 CORONA study was designed to assess whether baseline galectin-3 levels could distinguish a group of patients with heart failure who would derive a clinical benefit from rosuvastatin treatment. Rosuvastatin, known under the brand name CRESTOR(R), is a statin medication indicated for the treatment of high cholesterol and related lipid disorders to reduce the risk of heart attack and stroke. The sub-study involved 1,462 trial participants (approximately one-third of all CORONA trial subjects). Results demonstrated that patients with plasma levels of galectin-3 less than 19.0 ng/mL derived a 35% reduction in primary adverse cardiovascular events while on rosuvastatin treatment compared to placebo, while no comparable benefit was observed in subjects with plasma levels of galectin-3 above 19.0 ng/mL (p=0.036). The primary endpoint was a composite of cardiovascular mortality, non fatal myocardial infarction and non fatal stroke, which were analyzed as time to first event.

"Heart failure is a leading cause of death, and galectin-3 is increasingly recognized as a factor in promoting cardiac fibrosis and poor clinical outcomes in many heart failure patients," said Dr. Lars Gullestad, MD, PhD, Professor of Cardiology in the Department of Cardiology at Rikshospitalet University Hospital, Oslo, Norway, who led the study.

"This important study reaffirms a key premise of our galectin-3 research, namely that galectin-3 identifies heart failure patients with a distinct form of the disease," said Pieter Muntendam, MD, Executive Vice President and Chief Medical Officer of BG Medicine. "We expected that the benefit of certain drugs may be limited to patient groups defined by their level of galectin-3 and this is an excellent example of such differential benefit."

The original CORONA study was designed to evaluate the utility of rosuvastatin treatment for patients with advanced heart failure. Results from that trial, reported in the New England Journal of Medicine in 2007, demonstrated no rosuvastatin benefit on the primary coronary endpoint or on cardiovascular death.2

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD - News) is a life sciences company focused on the discovery, development and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3TM test for use in patients with heart failure, is available in the United States and Europe. BG Medicine has also developed CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.

The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352

Special Note Regarding Forward-looking Statements

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release address our expectations concerning the role that galectin-3 plays in heart failure and how therapeutic treatment decisions will be influenced by classification of heart failure patients according to galectin-3 levels, our expectations regarding the importance of the galectin-3 data published in the European Heart Journal, and the impact of the galectin-3 data on the sales and marketing of our galectin-3 diagnostic tests. Forward-looking statements are based on management's current expectations and involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Original post:

BG Medicine Announces Publication of First Study on Use of Galectin-3 in Selection of Drug Therapy in Heart Failure